Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis

被引：0

作者：

Massimo Breccia

Luigiana Luciano

Novella Pugliese

Elena Rossi

Mario Tiribelli

Emilia Scalzulli

Massimiliano Bonifacio

Bruno Martino

Roberto Latagliata

Giulia Benevolo

Giovanni Caocci

Gianni Binotto

Vincenzo Martinelli

Michele Cavo

Fabrizio Pane

Valerio De Stefano

Robin Foà

Francesca Palandri

机构：

[1] Sapienza University,Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I

[2] Federico II University,Institute of Hematology

[3] Fondazione Policlinico A. Gemelli IRCCS,Division of Hematology and BMT, Department of Medical Area

[4] Catholic University,Department of Medicine, Section of Hematology

[5] University of Udine,Division of Hematology

[6] University of Verona,Division of Hematology

[7] Azienda Ospedaliera ‘Bianchi Melacrino Morelli’,Department of Medical Sciences and Public Health, Hematology and Transplant Center, Businco Hospital

[8] Città della Salute e della Scienza Hospital,Unit of Hematology and Clinical Immunology

[9] University of Cagliari,Institute of Hematology “L. and A. Seràgnoli”

[10] University of Padova,undefined

[11] Sant’Orsola-Malpighi University Hospital,undefined

来源：

Annals of Hematology | 2019年 / 98卷

关键词：

Myelofibrosis; Ruxolitinib; Hydroxyurea; Efficacy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Ruxolitinib is the only commercially available JAK1/2 inhibitor approved for the treatment of myelofibrosis-related splenomegaly and symptoms. During treatment, as rare conditions, leukocytosis and/or thrombocytosis could develop and the management of these situations is not well established. We report here 53 myelofibrosis patients that received a combination of hydroxyurea and ruxolitinib because of uncontrolled myeloproliferation. Both drugs were administered outside clinical trials. At 48 weeks, a significant reduction in leucocyte and platelet counts was observed (p = 0.02 and p = 0.04, respectively). Additionally, the spleen volume decreased from a median value of 10 cm below the left costal margin (range, 0–10) to 6 cm (range, 0–15). The rate of spleen response increased from 14% at the start of the combination to 45% after 48 weeks. The safety profile of the combination was consistent with that observed with ruxolitinib single agent. These data require further confirmation in large cohorts of patients prospectively assessed.

引用

页码：1933 / 1936

页数：3

共 52 条

[1]

Arber DA(2016)The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Blood 127 2391-2405

[2]

Orazi A(2009)New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Blood 113 2895-2901

[3]

Hasserjian R(2012)A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis N Engl J Med 366 799-807

[4]

Cervantes F(2012)JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis N Engl J Med 366 787-798

[5]

Dupriez B(2016)Safety and efficacy of ruxolitinib in an open-label, multicentre, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial Haematologica 101 1065-1073

[6]

Pereira A(2016)Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis Leukemia 30 1701-1707

[7]

Verstovsek S(2017)Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis Oncotarget 8 79073-79086

[8]

Mesa RA(2017)Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations Leukemia 31 882-888

[9]

Gotlib J(2018)Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet Leukemia 32 1057-1069

[10]

Harrison C(2010)Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients Ann Hematol 89 1233-1237

← 1 2 3 4 5 6 →